Search

Your search keyword '"Thwaites, Ryan S"' showing total 207 results

Search Constraints

Start Over You searched for: Author "Thwaites, Ryan S" Remove constraint Author: "Thwaites, Ryan S"
207 results on '"Thwaites, Ryan S"'

Search Results

1. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease

2. Nasal cathelicidin is expressed in early life and is increased during mild, but not severe respiratory syncytial virus infection

3. High expression of oleoyl-ACP hydrolase underpins life-threatening respiratory viral diseases

4. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

5. Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms

7. Analysis of blood and nasal epithelial transcriptomes to identify mechanisms associated with control of SARS-CoV-2 viral load in the upper respiratory tract

8. A multi-country analysis of COVID-19 hospitalizations by vaccination status

9. Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

10. Nasal IL-13 production identifies patients with late-phase allergic responses

11. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

12. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

13. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

14. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

15. Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study

17. Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts

18. Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19.

19. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells

20. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

22. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study

23. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK

24. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK

25. Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study

26. Analysis of blood and nasal epithelial transcriptomes to identify mechanisms associated with control of SARS-CoV-2 viral load in the upper respiratory tract

28. A Genome-Wide Association Study of Respiratory Syncytial Virus Infection Severity in Infants.

29. Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults.

30. Natural killer cells and innate lymphoid cells but not NKT cells are mature in their cytokine production at birth.

31. Late Breaking Abstract - Large scale phenotyping of long COVID inflammation reveals mechanistic subtypes of disease.

33. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

34. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

36. SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection

37. Defining the balance between optimal immunity and immunopathology in influenza virus infection

38. Single‐cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.

41. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

42. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

43. Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

44. SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection

45. Procalcitonin is not a reliable biomarker of bacterial co-infection in people with COVID-19 undergoing microbiological investigation at the time of hospital admission

46. Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study

47. Additional file 1 of Modelling upper respiratory viral load dynamics of SARS-CoV-2

48. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

49. Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID‐19.

Catalog

Books, media, physical & digital resources